ParkinsonCanadaV1, France, Analysis, bibRecord, 000279

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset

Identifieur interne : 000279 ( France/Analysis ); précédent : 000278; suivant : 000280

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset

Auteurs : Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique]

Source :

Movement disorders [ 0885-3185 ] ; 2003.

RBID : Pascal:04-0130805

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Dyskinésie, Lévétiracétam, Anticonvulsivant, Lévodopa, Antiparkinsonien, Ropinirole, Chimiothérapie, Traitement associé, Animal, Modèle animal, Singe.
Wicri :
- topic : Singe.

English descriptors

KwdEn :
- Animal, Animal model, Anticonvulsant, Antiparkinson agent, Chemotherapy, Combined treatment, Dyskinesia, Levetiracetam, Levodopa, Monkey, Parkinson disease, Ropinirole.

Abstract

Long-term dopamine replacement therapy of Parkinson's disease leads to the occurrence of dyskinesias. Altered firing patterns of neurons of the internal globus pallidus, involving a pathological synchronization/desynchronization process, may contribute significantly to the genesis of dyskinesia. Levetiracetam, an antiepileptic drug that counteracts neuronal (hyper)synchronization in animal models of epilepsy, was assessed in the MPTP-lesioned marmoset model of Parkinson's disease, after coadministration with (1) levodopa (L-dopa) or (2) ropinirole/L-dopa combination. Oral administration of levetiracetam (13-60 mg/kg) in combination with either L-dopa (12 mg/kg) alone or L-dopa (8 mg/kg)/ropinirole (1.25 mg/kg) treatments was associated with significantly less dyskinesia, in comparison to L-dopa monotherapy during the first hour after administration. Thus, new nondopaminergic treatment strategies targeting normalization of abnormal firing patterns in basal ganglia structures may prove useful as an adjunct to reduce dyskinesia induced by dopamine replacement therapy without affecting its antiparkinsonian action.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000A24
to stream PascalFrancis, to step Curation: 000299
to stream PascalFrancis, to step Checkpoint: 000934
to stream Main, to step Merge: 003320
to stream Main, to step Curation: 002F16
to stream Main, to step Exploration: 002F16
to stream France, to step Extraction: 000279

Links to Exploration step

Pascal:04-0130805

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset</title>
<author><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Motac Neuroscience Ltd</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Basal Gang, CNRS UMR 5543, Universite Victor Segalen</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcguire, Steven G" sort="Mcguire, Steven G" uniqKey="Mcguire S" first="Steven G." last="Mcguire">Steven G. Mcguire</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Motac Neuroscience Ltd</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Motac Neuroscience Ltd</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>University of Manchester</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
<settlement type="city">Manchester</settlement>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Toronto Western Research Institute</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto Western Research Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Michel, Ann" sort="Michel, Ann" uniqKey="Michel A" first="Ann" last="Michel">Ann Michel</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>UCB S.A., Pharma Sector, Preclinical CNS Research</s1>
<s3>BEL</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>UCB S.A., Pharma Sector, Preclinical CNS Research</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grimee, Renee" sort="Grimee, Renee" uniqKey="Grimee R" first="Renee" last="Grimee">Renee Grimee</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>UCB S.A., Pharma Sector, Preclinical CNS Research</s1>
<s3>BEL</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>UCB S.A., Pharma Sector, Preclinical CNS Research</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Klitgaard, Henrik" sort="Klitgaard, Henrik" uniqKey="Klitgaard H" first="Henrik" last="Klitgaard">Henrik Klitgaard</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>UCB S.A., Pharma Sector, Preclinical CNS Research</s1>
<s3>BEL</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>UCB S.A., Pharma Sector, Preclinical CNS Research</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0130805</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 04-0130805 INIST</idno>
<idno type="RBID">Pascal:04-0130805</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A24</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000299</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000934</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000934</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Hill M:novel:antiepileptic:drug</idno>
<idno type="wicri:Area/Main/Merge">003320</idno>
<idno type="wicri:Area/Main/Curation">002F16</idno>
<idno type="wicri:Area/Main/Exploration">002F16</idno>
<idno type="wicri:Area/France/Extraction">000279</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset</title>
<author><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Motac Neuroscience Ltd</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Basal Gang, CNRS UMR 5543, Universite Victor Segalen</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcguire, Steven G" sort="Mcguire, Steven G" uniqKey="Mcguire S" first="Steven G." last="Mcguire">Steven G. Mcguire</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Motac Neuroscience Ltd</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Motac Neuroscience Ltd</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>University of Manchester</s1>
<s2>Manchester</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
<settlement type="city">Manchester</settlement>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Toronto Western Research Institute</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto Western Research Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Michel, Ann" sort="Michel, Ann" uniqKey="Michel A" first="Ann" last="Michel">Ann Michel</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>UCB S.A., Pharma Sector, Preclinical CNS Research</s1>
<s3>BEL</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>UCB S.A., Pharma Sector, Preclinical CNS Research</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grimee, Renee" sort="Grimee, Renee" uniqKey="Grimee R" first="Renee" last="Grimee">Renee Grimee</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>UCB S.A., Pharma Sector, Preclinical CNS Research</s1>
<s3>BEL</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>UCB S.A., Pharma Sector, Preclinical CNS Research</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Klitgaard, Henrik" sort="Klitgaard, Henrik" uniqKey="Klitgaard H" first="Henrik" last="Klitgaard">Henrik Klitgaard</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>UCB S.A., Pharma Sector, Preclinical CNS Research</s1>
<s3>BEL</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>UCB S.A., Pharma Sector, Preclinical CNS Research</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Animal model</term>
<term>Anticonvulsant</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Combined treatment</term>
<term>Dyskinesia</term>
<term>Levetiracetam</term>
<term>Levodopa</term>
<term>Monkey</term>
<term>Parkinson disease</term>
<term>Ropinirole</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Lévétiracétam</term>
<term>Anticonvulsivant</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Ropinirole</term>
<term>Chimiothérapie</term>
<term>Traitement associé</term>
<term>Animal</term>
<term>Modèle animal</term>
<term>Singe</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Long-term dopamine replacement therapy of Parkinson's disease leads to the occurrence of dyskinesias. Altered firing patterns of neurons of the internal globus pallidus, involving a pathological synchronization/desynchronization process, may contribute significantly to the genesis of dyskinesia. Levetiracetam, an antiepileptic drug that counteracts neuronal (hyper)synchronization in animal models of epilepsy, was assessed in the MPTP-lesioned marmoset model of Parkinson's disease, after coadministration with (1) levodopa (L-dopa) or (2) ropinirole/L-dopa combination. Oral administration of levetiracetam (13-60 mg/kg) in combination with either L-dopa (12 mg/kg) alone or L-dopa (8 mg/kg)/ropinirole (1.25 mg/kg) treatments was associated with significantly less dyskinesia, in comparison to L-dopa monotherapy during the first hour after administration. Thus, new nondopaminergic treatment strategies targeting normalization of abnormal firing patterns in basal ganglia structures may prove useful as an adjunct to reduce dyskinesia induced by dopamine replacement therapy without affecting its antiparkinsonian action.</div>
</front>
</TEI>
<affiliations><list><country><li>Belgique</li>
<li>Canada</li>
<li>France</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Aquitaine</li>
<li>Grand Manchester</li>
<li>Nouvelle-Aquitaine</li>
</region>
<settlement><li>Bordeaux</li>
<li>Manchester</li>
</settlement>
<orgName><li>Université de Manchester</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name>
</region>
<name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
<name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
<name sortKey="Mcguire, Steven G" sort="Mcguire, Steven G" uniqKey="Mcguire S" first="Steven G." last="Mcguire">Steven G. Mcguire</name>
</country>
<country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
</region>
</country>
<country name="Canada"><noRegion><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
</noRegion>
</country>
<country name="Belgique"><noRegion><name sortKey="Michel, Ann" sort="Michel, Ann" uniqKey="Michel A" first="Ann" last="Michel">Ann Michel</name>
</noRegion>
<name sortKey="Grimee, Renee" sort="Grimee, Renee" uniqKey="Grimee R" first="Renee" last="Grimee">Renee Grimee</name>
<name sortKey="Klitgaard, Henrik" sort="Klitgaard, Henrik" uniqKey="Klitgaard H" first="Henrik" last="Klitgaard">Henrik Klitgaard</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000279 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000279 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     Pascal:04-0130805
   |texte=   Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri